Brave new epigenomes: the dawn of epigenetic engineering by Anna Köferle et al.
Köferle et al. Genome Medicine  (2015) 7:59 
DOI 10.1186/s13073-015-0185-8COMMENT Open AccessBrave new epigenomes: the dawn of
epigenetic engineering
Anna Köferle1*, Stefan H. Stricker2,3* and Stephan Beck1*Editorial summary
New methods for epigenome editing now make it
possible to manipulate the epigenome in living cells
with unprecedented specificity and efficiency. These
ground-breaking approaches are beginning to yield
novel insights into the function of individual chromatin
marks in the context of cellular phenotype.‘toolbox’ (Table 1). These constructs can now be used asEnabling technologies
Our desire to manipulate genomes is not new; selective
breeding, genetic and, more recently, genome engineer-
ing have greatly advanced our understanding of how
genes shape phenotypes. On the cellular level, however,
differences in phenotype are mainly determined by
epigenetic processes. Millions of chromatin marks have
been profiled across the human genome in different
tissues and cell types. Yet, we are just beginning to
understand how chromatin-based mechanisms contrib-
ute to the establishment, control and inheritance of gene
activities. Epigenetic research has long been hindered by
the lack of experimental methods that would allow the
targeted manipulation of chromatin marks in living cells,
since mutational approaches and pharmacological inhib-
ition alter marks globally and nonspecifically. Epigenome
engineering now fills this gap, making it experimentally
possible to modify individual chromatin marks at spe-
cific user-defined sites. Targeted modification is achieved
by fusing an effector, usually an endogenous chromatin-
modifying enzyme or its minimal catalytic domain, to a
programmable DNA-binding domain. The DNA-binding
domain may be a synthetic zinc finger (ZF) or a TAL
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modifier is fused to a catalytically inactive version of the
Cas9 protein (dCas9), which is targeted via a separate,
synthetic RNA molecule known as the guide RNA
(gRNA). The base sequence of the gRNA determines the
DNA-binding specificity of the fusion protein. A range
of chromatin modifiers have already been engineered in
this way, representing the first components of an epigenetic
tools to address some fundamental questions concerning
the function of individual chromatin marks.First insights
It has long been unclear which of the large number of
chromatin marks that have been catalogued over the
years possess real gene-regulatory capabilities. Evidence
was based mainly on statistical association of chromatin
marks with expression levels of associated genes. How-
ever, it is worth bearing in mind that correlation does
not necessarily imply causation. The observation that
loss of chromatin modifiers causes strong phenotypes,
which can often be interpreted as a consequence of tran-
scriptional deregulation, provided further support. How-
ever, chromatin-modifier proteins also have non-histone
targets, and epigenetic marks play roles in chromatin-
based processes other than transcription. A causal role for
chromatin marks in regulation of transcription has been
convincingly demonstrated for some model loci, including
the Hox and imprinted gene clusters (for example [1]), but
it is still unclear whether these specific findings extend to
the vast remainder of the eukaryotic genome.
By directing chromatin modifiers to a range of sites at
different genomic loci and measuring resulting changes
in transcription of associated candidate genes, a number
of functional chromatin marks have now been identified.
For example, demethylating H3K4me2 at putative en-
hancers with TALE–LSD1 or dCas9–LSD1 leads to
downregulation of proximal genes [2, 3]. Likewise,
addition of H3K9 or DNA methylation successfully si-
lences a single gene promoter [4–6]. Removal of DNArticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Epigenetic toolbox: a list of targetable chromatin-modifier constructs reported to date
Construct Enzymatic function Target region Effect on gene expression Reference
dCas9–p300 Histone acetyltransferase,
transcriptional co-activator
Promoters and enhancers Between approximately 50-fold (OCT4, MYOD)
and 10,000-fold (IL1RN) upregulation when
targeted to promoters (qPCR); up to 300-fold





Promoter Between approximately 50-fold (HBB) and
more than 100–1,000-fold (RHOXF2) activation
over “off-target” controls (qPCR)
[7]
ZF–DNMT3a DNA methyltransferase Promoter Between approximately 0.5-fold and 0.2-fold
change (qPCR, western blot)
[5, 6]
ZF–G9a H3K9 methyltransferase Promoter Up to approximately 0.5-fold change (qPCR) [4]
TALE–LSD1 H3K4 and H3K9 demethylase Several candidate enhancers Up to approximately 0.4-fold change (RNA-seq) [2]
dCas9–LSD1 H3K4 and H3K9 demethylase Several candidate enhancers Up to approximately 0.02-fold change (qPCR) [3]
TALE–KYP, TALE–TgSET8,
TALE–NUE
Histone methyltransferases Promoter Up to approximately 0.3-fold change (qPCR) [10]
TALE–HDAC8, TALE–RPD3,
TALE–Sir2a, TALE–Sin3a
Histone deacetylase Promoter Up to approximately 0.3-fold change (qPCR) [10]
ZF + 223 different yeast
chromatin modifiers
Various Yeast pCYC1 Approximately 100-fold change (activators);
approximately 0.06-fold change (repressors)
[11]
qPCR quantitative PCR, TALE TAL protein, ZF synthetic zinc finger
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TET1 fusion proteins on the other hand results in sig-
nificant upregulation of transcription [7], and similar
results are achieved by histone acetylation at a handful
of promoters and enhancers using dCas9–p300 [8].
These first reports hold great promise for a general
applicability of epigenetic engineering, as they indicate
that both activation and silencing can be achieved by
single chromatin changes.
Open questions
Collectively, these studies show that manipulation of sin-
gle chromatin marks at relevant sites can significantly
alter levels of transcription and that this effect depends
on both the enzymatic activity of the chromatin modifier
and its binding to the target site. However, some ques-
tions remain regarding the efficiency of chromatin modi-
fication using synthetic modifiers. While epigenetic
editing can clearly influence transcription at a specific
site, manipulation in close vicinity often produces no
effect. This could reflect inherent differences in gene
regulatory potential between different loci. Alternatively,
it is possible that some sites cannot be modified effi-
ciently for technical reasons (such as dCas9 binding effi-
ciencies, transfection efficiencies), other layers of gene
regulation (for example, H3K27 methylation preventing
acetylation) or immediate reversal of the newly acquired
change (for example, by endogenous chromatin modifiers).
Thus, it remains to be addressed how many marks are
functional and where in the genome these must be located
in order to influence transcription.In addition to a more detailed investigation into the ef-
ficiency of targetable chromatin modifiers, it will be im-
portant to consider whether the reported transcriptional
changes are not just statistically significant, but also bio-
logically meaningful. To some extent this is a semantic
issue: while the term ‘gene activation’ suggests that gene
functions have been put into effect, it can also be used
to describe a minor increase in RNA levels relative to
background. It would be important to compare engi-
neered gene expression with physiological levels of ex-
pression where this is possible. In addition, analyses of
protein levels [5, 6] can ensure that engineered modifica-
tions are not affecting RNA processing or stability, and
that post-transcriptional processes do not compensate
for transcript levels. Ultimately, it will be vital to estab-
lish the effect of epigenome engineering on cellular
phenotype. Transcriptional downregulation through his-
tone demethylation has already been reported to lead to
loss of pluripotency [3]. It would be of great interest to
see whether transcriptional activation of reprogramming
factors, such as OCT4 [8], through epigenome engineer-
ing can also induce cellular identity changes, or whether
additional layers of gene regulation have to be manipu-
lated before functional effects can be achieved. Future
work should also elucidate the mechanistic details of
how chromatin modifications exert their influence on
transcription. Once the modification is added or re-
moved from a site of interest, are transcription factors
or other modifiers recruited and which are these? Which
factors are required for epigenetic engineering to proceed
efficiently and which are lacking if it does not?
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Effectively, we now have an emerging epigenetic
‘toolbox’ for epigenome engineering, ushering in a new
era of functional epigenomics. Based on the astonishing
pace with which this field is moving, more chromatin
modifiers will without doubt be added to the growing list
of available tools. We anticipate that it will soon be pos-
sible to dissect the effect of combinations of altered chro-
matin marks using orthologous targeting platforms.
The ease of targeting chromatin modifiers through an
RNA-based rather than protein-based DNA-binding
mechanism will further enable the unbiased discovery of
functional epigenetic marks using screening approaches.
Screens will constitute a significant step forward from
the analysis of the effect of a single mark on a single
locus enabling the interrogation of many potentially
functional marks in a single experiment. Libraries of
guide RNAs can be constructed that are either specific
to a limited range of loci of interest or potentially
unbiased and genome-wide. Loss-of-function genetic
screens and gain-of-function transcriptional activator
screens have already been implemented [9], but no
screening method has yet been reported using chromatin
modifiers. Since epigenetic screens are geared towards
phenotypic read-outs, they will be instrumental in ad-
dressing the open questions formulated above. Only sites
where chromatin modifications have significant impact,
not only on transcription, but also on phenotype, will be
reported as hits.
Eventually, some of the findings may be expected to
be translated into therapeutic use by adopting epigenetic
engineering technologies for in vivo situations. There are
already first indications that this may be feasible based
on targeted epigenetic engineering of candidate pro-
moters in the brain of living mice, positively affecting
addiction-related and depression-related behavior [4].
However, to ensure that those anticipated ‘brave new
epigenomes’ are not confused with the fictional ‘brave
new world’, we should today, with scientific rigor and
informed regulation, start discussing any ensuing ethical,
legal and social implications of somatic and germline
epigenetic engineering.
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